中药对比安慰剂治疗慢性阻塞性肺疾病稳定期的系统评价与Meta分析
OBJECTIVE: Randomized clinical trials and published meta-analyses assessing the clinical effectiveness of Chinese herbal medicine (CHM) on the treatment of stable chronic obstructive pulmonary disease (COPD) yielded inconsistent results in terms of disease outcomes, in which the …
要点
- 在常规西药基础上加用中药可改善稳定期COPD患者症状评分和生活质量
- 中药可减少急性加重频率并提高临床有效率,但对FEV1%pred无显著改善
- 未报告与中药相关的严重不良事件,但证据需高质量试验进一步验证
核心结论
- 在维持常规西药治疗基础上,中药可缓解稳定期COPD临床症状、改善生活质量、提高临床有效率并减少急性加重频率。
- 中药是相对安全的治疗选择,可作为COPD治疗调整的替代方法,但结论需未来高质量临床试验验证。
研究设计与样本
- 系统评价与Meta分析,检索9个电子数据库从建库至2019年10月1日,纳入英文或中文的安慰剂对照随机试验。
- 主要结局为症状评分(CAT)、生活质量(SGRQ)和急性加重频率,次要结局包括肺功能、临床总有效率和不良事件。
主要发现
- 在维持常规西药治疗下,中药对比安慰剂改善CAT评分(MD -3.93;95%CI -6.01至-1.85)。
- 中药对比安慰剂改善SGRQ评分(MD -6.20;95%CI -10.13至-2.28)。
- 中药对比安慰剂减少急性加重频率(MD -0.78;95%CI -1.40至-0.16)。
- 中药对比安慰剂提高临床有效率(RR 1.29;95%CI 1.14至1.45)。
- 中药对比安慰剂对FEV1%pred无显著影响(MD 8.18;95%CI -4.22至20.58),急性加重频率和FEV1%pred变化存在高异质性。
关键数值与推荐
- 主要结局指标为CAT评分、SGRQ评分和急性加重频率。
- 连续变量采用均数差(MD)分析,二分类变量采用相对危险度(RR)分析。
- 未报告与中药相关的严重不良事件。
临床怎么用
- 对稳定期COPD患者,可在常规西药治疗基础上考虑加用中药以改善症状、生活质量和减少急性加重。
- 不应期望中药能显著改善FEV1%pred,临床决策需结合患者具体情况。
- 使用中药时仍需关注安全性,尽管本研究中未报告与中药相关的严重不良事件。
局限性
- 急性加重频率和FEV1%pred变化存在高异质性。
- 检索截止至2019年10月1日,未纳入此后发表的研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Randomized clinical trials and published meta-analyses assessing the clinical effectiveness of Chinese herbal medicine (CHM) on the treatment of stable chronic obstructive pulmonary disease (COPD) yielded inconsistent results in terms of disease outcomes, in which the design of placebo-controlled studies can contribute to the heterogeneity. This study aimed to evaluate the efficacy and safety of CHM compared to placebo on the treatment of stable COPD, to provide robust evidence for the use of CHM in COPD. METHODS: Nine electronic databases were searched from inception to October 1, 2019 to identify placebo controlled randomized trials of CHM for the treatment of stable COPD and studies in English or Chinese were included. The primary outcomes were symptom score (CAT score), quality of life (SGRQ) and frequency of acute exacerbations. The secondary outcomes included lung function, clinical total effective rate and adverse events. The selection of studies, data extraction and coding and assessment of risk of bias of the included studies were conducted by two reviewers independently. Mean difference (MD) was used to analyze continuous variable and relative risk ratio (RR) for dichotomous data. RESULTS: A total of eleven studies involving 1223 patients were included. While maintaining routine western pharmacotherapies (WP), CHM had significant advantage over the treatment of placebo in improving CAT score (MD -3.93; 95 %CI -6.01 to -1.85) and SGRQ score (MD -6.20; 95 %CI -10.13 to -2.28), reducing the frequency of acute exacerbations (MD -0.78; 95 %CI -1.40 to -0.16) and improving clinical effective rate (RR 1.29; 95 %CI 1.14 to 1.45), but had no significant effect on improving FEV1%pred (MD 8.18; 95 %CI -4.22 to 20.58). High heterogeneity was found for the changes in exacerbation frequency and FEV1%pred. No serious adverse events related to CHM were reported. CONCLUSIONS: This meta-analysis of placebo-controlled RCTs demonstrated that the use of CHM in addition to WP could alleviate clinical symptoms, improve quality of life and clinical efficiency and reduce the frequency of exacerbations, which could be an alternative approach for treatment adjustment of COPD. CHM was a relatively safe treatment. These findings need to be verified in future with high-quality clinical trials.
引用
- Xiong C, Li Y, Zhuang G, et al. Clinical efficacy and safety of Chinese herbal medicine versus placebo for the treatment of chronic obstructive pulmonary disease: A systematic review and meta-analysis. Complement Ther Med. 2021. PMID: 33618010. doi:10.1016/j.ctim.2021.102691
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。